12,372 trials
Complicated Intra-abdominal Infection · Hosptial Acquired Pneumonia · Ventilator Associated Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set — 68.4; 65.7 Percentage of participants
Metastatic Castration-Resistant Prostate Cancer · Ovarian Cancer · Epithelial Ovarian Cancer
Primary: Number of Participants Experiencing SAEs and AESIs — 2; 0 Participants
Adenovirus Infection · BK Virus Infection · Cytomegalovirus Infections
Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants
Emergency Contraception
Primary: Percentage of Pregnancies Prevented — 94.7; 63.3 percentage of pregnancies prevented — p=<0.0001
Wet Age-related Macular Degeneration
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. — 2.5; 4.6 ETDRS Letters — p=0.0083
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Primary: PFS((Progression-Free Surviv) — 5.7; 5.5 months
Pneumonia, Pneumococcal
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) — 7.4; 7.7; 7.5; 9.4 Percentage of Participants
Gliosarcoma · MGMT-Unmethylated Glioblastoma
Primary: Progression-free Survival (PFS) (Phase II) — 8.5; 7.7 months — p=0.96
Endometriosis
Primary: Dysmenorrhea — 62; 101; 32; 43 Participants
Focal Segmental Glomerulosclerosis
Primary: Slope of Estimated Glomerular Filtration Rate (eGFR) — -5.4; -5.7 milliliters/minute/1.73square meter/year — p=0.7491
Homozygous Familial Hypercholesterolemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216 — 93; 27 Number of participants
Chronic Migraine, Headache · Episodic Migraine
Primary: Mean Change in Pain Intensity Scores Measured by the Numeric Analog Scale (NRS) — 2.3; 1.1 score on a scale — p=0.013
Cystic Fibrosis
Primary: Time to an Exacerbation — 58; 51.5 Days — p=0.0715
Major Depressive Disorder
Primary: The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 96.8; 93.1 percentage of participants
Covid19 · SARS-CoV-2
Primary: Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of…